References
- Gross S, Cairns RA, Minden MD, et al Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339–344.
- Ward PS, Patel J, Wise DR, et al The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:215–216.
- Mardis ER, Ding L, Dooling DJ, et al Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–1066.
- Marcucci G, Maharry K, Wu YZ, et al IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–2355.
- Thol F, Damm F, Wagner K, et al Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614–616.
- Yan H, Parsons W, Jin G, et al IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773.
- Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009;68:1319–1325.
- Dohner H, Estey EH, Amadori S, et al Diagnosis and management of acute myeloid in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.